Navigation Links
A First-Line Therapy for Renal Cell Carcinoma that can Increase Overall Survival when Compared with Sutent Would Earn a Higher Patient Share in the United States Than in Europe
Date:2/26/2009

Pfizer's Axitinib Earns Decision Resources' Gold-Standard for Renal Cell Carcinoma in 2012, According to a New Report from Decision Resources

WALTHAM, Mass., Feb. 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a first-line therapy for metastatic renal cell carcinoma that can increase overall survival in comparison with Pfizer's Sutent would earn a 50 percent patient share in the United States and a 35 percent patient share in Europe, according to surveyed U.S. and European oncologists.

The new report entitled Renal Cell Carcinoma (Metastatic): Axitinib's Improvements in Overall Survival will Differentiate it from Current and Emerging Therapies finds that a therapy's effect on overall survival is the attribute that most influences surveyed oncologists' prescribing decisions in metastatic renal cell carcinoma. Clinical data and the opinions of interviewed thought leaders indicate that Pfizer's axitinib has advantages over Sutent in this attribute. Sutent, the market sales leading agent, was Decision Resources' proprietary clinical gold standard in 2008 for metastatic renal cell carcinoma.

Based on available data and expert opinion, axitinib will earn gold-standard status for metastatic renal cell carcinoma in 2012 through 2017, following its approval for the indication in 2011. Interviewed experts anticipate that axitinib, which has competitive advantages and has shown impressive Phase II survival data in the second-line setting, will be more effective than Sutent.

"In the second-line setting, axitinib has shown an increase in median overall survival in clinical trials," said Decision Resources Analyst Laila Siddique. "This median overall survival is slightly longer than the overall survival observed with Sutent in the first-line setting. Axitinib's data are particularly impressive because patients receiving second-line therapies generally have a poorer prognosis than patients in the first-line setting."

About the Report

Renal Cell Carcinoma (Metastatic): Axitinib's Improvements in Overall Survival will Differentiate it from Current and Emerging Therapies is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                          Decision Resources, Inc.
    Christopher Comfort                         Elizabeth Marshall
    781-296-2597                                781-296-2563
    ccomfort@dresources.com                     emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer
2. Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkins Lymphoma
3. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
4. Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
5. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
6. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
7. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
8. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
9. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
10. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
11. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016  Aralez Pharmaceuticals Inc. ... of POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") ... and shareholders of Tribute. The combined company will operate ... company with operations in Canada , ... United States . Under the terms of the ...
(Date:2/5/2016)... February 5, 2016 --> ... report states that the global active pharmaceuticals ingredients (APIs) ... predicted to reach US$185.9 bn by 2020. It is ... 2014 to 2020. The title of the report is ... by Geography, and by Therapeutic Area) - Global Industry ...
(Date:2/5/2016)... Feb. 5, 2016  Henry Schein, Inc. (NASDAQ: HSIC ... and services to office-based dental, animal health and medical ... agreement to acquire a majority ownership interest in Dental ... in Brazil . ... Dental Cremer is the dental distribution business of Cremer ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being ... Block Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for ... of Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative ...
(Date:2/5/2016)... ... , ... After years as an active staff surgeon and having served as ... Wayne Carman transitioned to chief of the Division of Plastic Surgery at what is ... chief and began a second three-year term in January of 2016. , The original ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know ... having to wait longer to access the treadmills. It’s a predictable trend. After the ... lose weight and get in shape by joining gyms, starting new walking or running ...
(Date:2/5/2016)... Georgia (PRWEB) , ... February 05, 2016 , ... Dr. ... to announce their 2nd Annual No Cost Dental Day to individuals in need. The ... The purpose of this No Cost Dental Day is to provide dental care to ...
(Date:2/5/2016)... ... February 05, 2016 , ... Health and wellness is a topic that should ... event they are experiencing an illness. Migraines are a severe form of a headache ... migraines would not wish the pain on their worst enemy, the feeling can last ...
Breaking Medicine News(10 mins):